AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (52)

Latest Posts

About This Stock More About This Stock
AstraZeneca's Q1 Earnings & Sales Miss, Stock Down
Article By: Zacks Investment Research
Friday, May 18, 2018 12:13 PM EDT
This year so far, AstraZeneca’s shares have risen 5.0% against the industry’s decline of 3.8%.
In this article: AZN Also: LLY, MRK, LGND
Read
Week In Review: $3.4 Billion Week For China Life Science Deals
Article By: ChinaBio® Today
Saturday, May 12, 2018 4:50 PM EDT
Armo Biosciences, a Bay Area immuno-oncology company, agreed to be acquired by Eli Lilly. Lilly offered to pay $50 per share for Armo, a three-fold increase from the IPO price and a 67% jump from its previous close.
In this article: AZN, LLY, ARMO, GILD
Read
AstraZeneca (AZN) Beats On Q4 Earnings, Guides For 2018
Article By: Zacks Investment Research
Friday, February 2, 2018 10:30 AM EDT
AstraZeneca plc reported fourth-quarter 2017 core earnings of 65 cents per American Depositary Share (ADS), which beat the Zacks Consensus Estimate of 45 cents. Core earnings rose 13% year over year at constant exchange rates (CER).
In this article: AZN Also: MRK, INCY, ABBV
Read
3 Large Cap Pharma Stocks To Beat Earnings This Quarter
Article By: Zacks Investment Research
Tuesday, January 23, 2018 4:55 PM EDT
The fourth-quarter earnings season is in full swing and the trend so far appears impressive.
In this article: AZN, MRK, ABBV
Read
Week In Review: Hua Medicine To Raise $200 Million Through Fundings And IPO For Oral Diabetes Drug
Article By: ChinaBio® Today
Saturday, January 13, 2018 6:23 PM EDT
Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US.
In this article: VRACY, BSTG, VAR, AZN, BMY, AMGN, BGNE
Read

PARTNER HEADLINES

Latest Tweets for $AZN

No tweets yet!